Radionuclide imaging in cardio-oncology: A clinical decision-making tool
Progress in Cardiovascular Diseases · 2025-11 · 93 · 66-74
DOI: 10.1016/j.pcad.2025.09.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2025-11. Verfasst von Teodora Donisan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States of America. Hauptthemen laut MEDLINE: Clinical Decision-Making, Neoplasms, Heart Diseases, Medical Oncology. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 79 Literaturangaben.
Abstract (Originalsprache)
Nuclear cardiology has become an integral component of cardiovascular care in oncology, providing robust tools for the detection, monitoring, and mechanistic assessment of cancer therapy-related cardiac dysfunction. This review outlines the evolving applications of nuclear imaging across the cardio-oncology continuum, from reproducible quantification of left ventricular ejection fraction with multigated acquisition to advanced molecular imaging with positron emission tomography for the identification of pathobiology. We discuss the utility of radionuclide techniques for early detection of subclinical cardiotoxicity, including phase analysis, metabolic imaging with 18F-fluorodeoxyglucose, and emerging tracers targeting inflammation, fibrosis, and immune cell activity. Special considerations are given to their role in differentiating ischemic from non-ischemic injury, evaluating cardiac tumors, and guiding therapeutic decisions. Comparative strengths and limitations relative to other imaging modalities are briefly addressed, along with practical considerations such as access, and modality selection. Looking forward, developments in hybrid imaging, artificial intelligence, and targeted radiotracers are poised to enhance risk stratification and enable personalized, mechanism-based cardioprotection. Nuclear cardiology, when integrated thoughtfully into multimodal strategies, will be essential to advancing precision care in cardio-oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States of America.
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States of America.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States of America. Electronic address: rodriguez.m@mayo.edu.
Zitieren
APA
Donisan, T., Sykora, D., Balanescu, D. V., Chang, I. C., Lin, G., Herrmann, J., & Rodriguez-Porcel, M. (2025). Radionuclide imaging in cardio-oncology: A clinical decision-making tool. Progress in Cardiovascular Diseases, 93, 66-74. https://doi.org/10.1016/j.pcad.2025.09.008
Vancouver
Donisan T, Sykora D, Balanescu DV, Chang IC, Lin G, Herrmann J, et al. Radionuclide imaging in cardio-oncology: A clinical decision-making tool. Progress in Cardiovascular Diseases. 2025;93:66-74. doi:10.1016/j.pcad.2025.09.008
BibTeX
@article{Donisan2025,
author = {Donisan, Teodora and Sykora, Daniel and Balanescu, Dinu V and Chang, Ian C and Lin, Grace and Herrmann, Joerg and Rodriguez-Porcel, Martin},
title = {Radionuclide imaging in cardio-oncology: A clinical decision-making tool},
journal = {Progress in Cardiovascular Diseases},
year = {2025},
volume = {93},
pages = {66--74},
doi = {10.1016/j.pcad.2025.09.008}
}
EUVIMED